RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Reistone, a one-year-old Shanghai-Beijing-Boston biopharma, has dosed the first patient in global Phase II trial of its JAK1 inhibitor in patients with Ulcerative Colitis and Crohn’s disease. The JAK1 candidate was developed by Jiangsu Hengrui. In early 2018, Hengrui established Reistone, complete with financial backing, as a company capable of conducting global trials of China-discovered drugs, Hengrui’s own and those of other companies. The JAK1 clinical trial is a randomized, double-blind, placebo-controlled, four-armed, multi-center Phase II test with safety and efficacy endpoints.
Source: China Biotoday
